Quality of life and symptom changes over two years in adults with CLL or SLL starting targeted therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort enrolls adults with pathology-confirmed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within seven days of beginning treatment with either a Bruton's tyrosine kinase inhibitor (BTKi) — with or without an anti-CD20 antibody — or a BCL2 inhibitor given with obinutuzumab. Participants complete standardized patient-reported outcome measures of quality of life, fatigue, and symptoms at scheduled intervals and are followed for two years. Analyses will compare the trajectories of these patient-reported outcomes between the two treatment groups while adjusting for clinical and demographic factors. The study is conducted at H. Lee Moffitt Cancer Center in collaboration with the NCCN and industry partners.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
* Subjects must be able to read and speak English or Spanish at the 8th grade level.

Exclusion Criteria:

* Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

Study contacts

• Principal investigator: Sara Tinsley-Vance, PhD, APRN, AOCN — Moffitt Cancer Center
• Study coordinator: Daniel Lastorino
• Email: Daniel.Lastorino@moffitt.org
• Phone: 813-745-0092

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

  This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

  Recruiting European Research Initiative on CLL · Milan · NCT07774390

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy

  NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.

  Recruiting at 43 sites Phase 2 Nurix Therapeutics, Inc. · Phoenix, Arizona and 42 other locations · NCT07221500

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• Long-term safety of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788639

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.